Target Name: GZMH
NCBI ID: G2999
Review Report on GZMH Target / Biomarker Content of Review Report on GZMH Target / Biomarker
GZMH
Other Name(s): Cytotoxic serine protease C | cytotoxin serine protease-C | CGL2 | Cytotoxic T-lymphocyte-associated serine esterase 1 | Cytotoxin serine protease-C | GZMH variant 1 | cytotoxic T-lymphocyte proteinase | Cathepsin G-like 2 | cytotoxic T-lymphocyte-associated serine esterase 1 | Granzyme H | CCP-X | Granzyme H, transcript variant 1 | granzyme H | GRAH_HUMAN | cathepsin G-like 2, protein h-CCPX | CGL-2 | CSP-C | CTLA1 | Granzyme H (isoform 1) | CTSGL2 | Cytotoxic T-lymphocyte proteinase

Understanding GZMH: A Potential Drug Target

GZMH (Cytotoxic serine protease C) is a protein that is expressed in a wide range of tissues throughout the body, including the liver, lung, and kidney. It is a member of the serine proteases family 11, which includes a number of enzymes that play important roles in cellular signaling and homeostasis. One of the functions of GZMH is to regulate the levels of cell surface proteins, and it is known to be involved in the processes of cell signaling, migration, and apoptosis.

GZMH is also a potential drug target, as it has been shown to be involved in a number of diseases and disorders. For example, GZMH has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease . It has also been shown to be involved in the development of cancer, and to contribute to the development of a number of diseases, including heart disease, diabetes, and liver disease.

In addition to its potential clinical applications, GZMH is also of interest to researchers because of its unique structure and biology. GZMH is a member of the serine proteases family 11, and is characterized by a catalytic active site that is composed of a variable number of amino acids. This variability makes it difficult to predict the unique three-dimensional structure of GZMH, and has allowed researchers to use a variety of techniques to study its behavior.

One of the challenges in studying GZMH is its tendency to be expressed in a wide range of tissues, and to be involved in a variety of cellular processes. This makes it difficult to study its function in a specific context, and to determine how it contributes to the development and progression of various diseases. However, research into GZMH is ongoing, and it is likely that new insights into its biology and function will emerge in the future.

In conclusion, GZMH is a protein that is of interest to researchers due to its unique structure and biology. Its potential clinical applications and involvement in the development of a variety of diseases make it a promising target for future research. While more work is needed to fully understand its function and potential, the study of GZMH is an important step in the search for new treatments and therapies.

Protein Name: Granzyme H

Functions: Cytotoxic chymotrypsin-like serine protease with preference for bulky and aromatic residues at the P1 position and acidic residues at the P3' and P4' sites. Probably necessary for target cell lysis in cell-mediated immune responses. Participates in the antiviral response via direct cleavage of several proteins essential for viral replication

The "GZMH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GZMH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GZMK | GZMM | H1-0 | H1-1 | H1-10 | H1-10-AS1 | H1-2 | H1-3 | H1-4 | H1-5 | H1-6 | H1-7 | H1-8 | H1-9P | H19 | H19-ICR | H2AB1 | H2AB2 | H2AB3 | H2AC1 | H2AC11 | H2AC12 | H2AC13 | H2AC14 | H2AC15 | H2AC16 | H2AC17 | H2AC18 | H2AC20 | H2AC21 | H2AC25 | H2AC3P | H2AC4 | H2AC6 | H2AC7 | H2AJ | H2AP | H2AX | H2AZ1 | H2AZ1-DT | H2AZ2 | H2AZ2-DT | H2AZP2 | H2BC1 | H2BC10 | H2BC11 | H2BC12 | H2BC12L | H2BC13 | H2BC14 | H2BC15 | H2BC17 | H2BC18 | H2BC20P | H2BC21 | H2BC26 | H2BC27P | H2BC3 | H2BC4 | H2BC5 | H2BC6 | H2BC7 | H2BC8 | H2BC9 | H2BP1 | H2BP2 | H2BP3 | H2BW1 | H2BW2 | H2BW4P | H3-3A | H3-3B | H3-4 | H3-5 | H3-7 | H3C1 | H3C10 | H3C11 | H3C12 | H3C13 | H3C14 | H3C15 | H3C2 | H3C3 | H3C4 | H3C6 | H3C7 | H3C8 | H3P16 | H3P36 | H3P37 | H3P44 | H3P5 | H3P6 | H4C1 | H4C11 | H4C12 | H4C13 | H4C14 | H4C15